Risk Factors for MRSA Cellulitis
While MRSA is an uncommon cause of typical cellulitis, specific risk factors should prompt empiric MRSA coverage: penetrating trauma (especially from injection drug use), purulent drainage, concurrent MRSA infection elsewhere, presence of abscesses, and obesity. 1, 2
Key Clinical Context
The IDSA guidelines emphasize that MRSA is actually an unusual cause of typical cellulitis—a prospective study showed β-lactam therapy (cefazolin/oxacillin) was successful in 96% of cellulitis cases, indicating MRSA treatment is usually unnecessary 1. However, recognizing when MRSA is likely is critical to avoid treatment failure.
Primary Risk Factors for MRSA Cellulitis
Patient-Specific Factors:
- Injection drug use (strongest association) 3
- Obesity (independent risk factor with adjusted OR 2.33) 2, 4
- Previous MRSA infection or colonization (OR 6.4) 3
- Diabetes mellitus (OR 4.1) 3
- Advanced age (median 74 years vs 61 for MSSA) 5
- Greater loss of autonomy/comorbidities 5
Clinical Presentation Features:
- Presence of abscesses (strongest predictor with adjusted OR 2.72) 2, 3
- Purulent drainage 1
- Penetrating trauma 1
- Lesions involving head and neck 2
Healthcare-Related Factors:
- Recent antibiotic use (within preceding 8 weeks; OR 2.6) 3
- Hospital admission in previous 12 months (OR 2.6) 3
- Intravascular devices or implantable cardiac devices 6
Important Clinical Pitfalls
The absence of purulent drainage, abscess, or ulcer strongly suggests streptococcal etiology—in these cases, β-lactam monotherapy is recommended rather than MRSA coverage 1. This is substantiated by a double-blind study showing SMX-TMP plus cephalexin was no more efficacious than cephalexin alone in pure cellulitis 1.
Local Epidemiology Considerations
MRSA prevalence varies dramatically by location and time. One Canadian ED study showed MRSA SSTI prevalence increased from 21% (January 2003) to 68% (September 2004), with overall period prevalence of 54.8% 3. A Pennsylvania population study demonstrated CA-MRSA incidence increased by 34% annually from 2005-2009 4. Clinicians must know their local MRSA prevalence patterns to guide empiric therapy decisions.
When to Cover MRSA Empirically
Coverage for MRSA is prudent when:
- Penetrating trauma present, especially from illicit drug use
- Purulent drainage visible
- Abscess formation identified
- Concurrent MRSA infection at another site
- Patient has obesity plus other risk factors
- Recent antibiotic failure on β-lactam therapy
Do NOT routinely cover MRSA for:
- Typical non-purulent cellulitis without risk factors
- Absence of abscess, ulcer, or purulent drainage
- No history of MRSA or high-risk exposures
Additional Risk Factors from Population Studies
Community-level factors include season, community socioeconomic deprivation, and smoking 4. However, these are less actionable for individual treatment decisions compared to the patient-specific and clinical presentation factors above.